Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without tremelimumab plus chemotherapy versus chemotherapy in first-line advanced urothelial cancer
2018-001883-48Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) and bladder cancer comparing Durvalumab + standard-of-care chemotherapy, Durvalumab + tremelimumab + standard-of-care chemotherapy and Standard-of-care chemotherapy alone (3 arms). Primary endpoint: Overall survival. Started Aug 2018; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2018-001883-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001883-48.